Claus Schalper News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Claus schalper. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Claus Schalper Today - Breaking & Trending Today
StockNews.com initiated coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) in a research note issued to investors on Thursday. The firm issued a hold rating on the biotechnology company’s stock. Pieris Pharmaceuticals Stock Down 4.6 % PIRS stock traded down $0.04 during trading on Thursday, reaching $0.82. The company had a trading volume […] ....
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) is set to announce its earnings results after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Investors that are interested in registering for the company’s conference call can do so using this link. Pieris Pharmaceuticals Stock […] ....
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) shares passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $1.12 and traded as low as $0.72. Pieris Pharmaceuticals shares last traded at $0.74, with a volume of 755,081 shares changing hands. Wall Street Analysts Forecast […] ....
Pieris Pharmaceuticals (NASDAQ:PIRS – Get Rating) is scheduled to announce its earnings results after the market closes on Tuesday, May 9th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Pieris Pharmaceuticals Price Performance NASDAQ:PIRS opened at $0.77 on Wednesday. Pieris Pharmaceuticals has a 1-year low of $0.72 and a […] ....
Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS – Get Rating) – Equities researchers at Jefferies Financial Group issued their FY2027 earnings per share estimates for shares of Pieris Pharmaceuticals in a research note issued to investors on Wednesday, March 29th. Jefferies Financial Group analyst R. Song anticipates that the biotechnology company will post earnings per share of ($0.38) […] ....